When considering BRAF mutant PTCs, HT was associated with a 75% reduced risk of lymph node infiltration when compared to patients without underlying HT (OR = 0.25, 95%CI = 0.11–0.58, p = 0.001). This evidence concerns the gene BRAF and hematocrit.